Paradiem’s Genmab GMAB Stock Holding History

Paradiem’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-28,904	Closed	-$1.3M	–	103
2021 Q3	$1.3M	Buy	28,904 +1,267	+5%	+$56.9K	0.39%	85
2021 Q2	$1.29M	Buy	27,637 +1,748	+7%	+$67.5K	0.4%	84
2021 Q1	$921K	Buy	25,889 +11,223	+77%	+$422K	0.3%	85
2020 Q4	$590K	Buy	+14,666	New	+$548K	0.25%	85

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paradiem's GMAB Position: Q4 2021 in Review

Paradiem sold out of Genmab (GMAB) in Q4 2021, closing a stake of 28,904 shares — an estimated $1.3M sold.

Paradiem first reported a position in GMAB in Q4 2020 and held it in 4 quarters. The position peaked at $1.3M in Q3 2021. 211 funds tracked by Wall St. Rank hold GMAB as of Q4 2021.

Paradiem reported no remaining Genmab position as of Q4 2021 after selling out during the quarter.
Paradiem sold 28,904 Genmab shares in Q4 2021, an estimated $1.3M.
Paradiem first reported a position in Genmab in Q4 2020 and held it in 4 quarters.
Paradiem's Genmab position peaked at $1.3M in Q3 2021.
211 funds tracked by Wall St. Rank held Genmab as of Q4 2021.

Based on Paradiem's 13F filing for Q4 2021, filed 3 Feb 2022.